The biomarker specialists at Biomedica Immunoassays, announced the launch of the first CE marked FGF23 (C-terminal) ELISA assay which specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. The FGF23 ELISA assay complements the existing Biomedica assays directed against chronic kidney disease – mineral and bone disorder (CKD-MBD) in a growing collection.
The FGF23 ELISA assay will be an important tool for researchers investigating new biomarkers that could improve prediction of CKD progression, as well as discovery of new drug targets. The FGF23 ELISA assay provides researchers with a powerful solution for drug discovery and translational research.
CKD affects millions of people every year, and is rapidly increasing. There is a great unmet need in predicting CKD progression and in gauging the efficacy of treatment options at an individual level. Novel biomarkers are central in personalized medicine and important for improving healthcare in general through earlier diagnostic and better prognosis.
